Un­der a short as­sault, Cor­bus coun­ter­at­tacks with pos­i­tive PhII da­ta for sys­temic scle­ro­sis drug

Cor­bus Phar­ma­ceu­ti­cals says that its sole clin­i­cal-stage drug came through in a small Phase II study for sys­temic scle­ro­sis, an au­toim­mune dis­ease of con­nec­tive tis­sue …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER